Putting artificial intelligence at the heart of health care with help from MIT – MIT News

Artificial intelligence is transforming industries around the world and health care is no exception. A recent Mayo Clinic study found that AI-enhanced electrocardiograms (ECGs) have the potential to save lives by speeding diagnosis and treatment in patients with heart failure who are seen in the emergency room.

The lead author of the study is Demilade Demi Adedinsewo, a noninvasive cardiologist at the Mayo Clinic who is actively integrating the latest AI advancements into cardiac care and drawing largely on her learning experience with MIT Professional Education.

Identifying AI opportunities in health care

A dedicated practitioner, Adedinsewo is a Mayo Clinic Florida Women's Health Scholar and director of research for the Cardiovascular Disease Fellowship program. Her clinical research interests include cardiovascular disease prevention, women's heart health, cardiovascular health disparities, and the use of digital tools in cardiovascular disease management.

Adedinsewos interest in AI emerged toward the end of her cardiology fellowship, when she began learning about its potential to transform the field of health care. I started to wonder how we could leverage AI tools in my field to enhance health equity and alleviate cardiovascular care disparities, she says.

During her fellowship at the Mayo Clinic, Adedinsewo began looking at how AI could be used with ECGs to improve clinical care. To determine the effectiveness of the approach, the team retroactively used deep learning to analyze ECG results from patients with shortness of breath. They then compared the results with the current standard of care a blood test analysis to determine if the AI enhancement improved the diagnosis of cardiomyopathy, a condition where the heart is unable to adequately pump blood to the rest of the body. While she understood the clinical implications of the research, she found the AI components challenging.

Even though I have a medical degree and a masters degree in public health, those credentials arent really sufficient to work in this space, Adedinsewo says. I began looking for an opportunity to learn more about AI so that I could speak the language, bridge the gap, and bring those game-changing tools to my field.

Bridging the gap at MIT

Adedinsewos desire to bring together advanced data science and clinical care led her to MIT Professional Education, where she recently completed the Professional Certificate Program in Machine Learning & AI. To date, she has completed nine courses, including AI Strategies and Roadmap.

All of the courses were great, Adedinsewo says. I especially appreciated how the faculty, like professors Regina Barzilay, Tommi Jaakkola, and Stefanie Jegelka, provided practical examples from health care and nonhealth care fields to illustrate what we were learning.

Adedinsewos goals align closely with those of Barzilay, the AI lead for the MIT Jameel Clinic for Machine Learning in Health. There are so many areas of health care that canbenefit from AI, Barzilay says. Its exciting to see practitioners like Demijoin the conversation and help identify new ideas for high-impact AIsolutions.

Adedinsewo also valued the opportunity to work and learn within the greater MIT community alongside accomplished peers from around the world, explaining that she learned different things from each person. It was great to get different perspectives from course participants who deploy AI in other industries, she says.

Putting knowledge into action

Armed with her updated AI toolkit, Adedinsewo was able to make meaningful contributions to Mayo Clinics research. The team successfully completed and published their ECG project in August 2020, with promising results. In analyzing the ECGs of about 1,600 patients, the AI-enhanced method was both faster and more effective outperforming the standard blood tests with a performance measure (AUC) of 0.89 versus 0.80. This improvement could enhance health outcomes by improving diagnostic accuracy and increasing the speed with which patients receive appropriate care.

But the benefits of Adedinsewos MIT experience go beyond a single project. Adedinsewo says that the tools and strategies she acquired have helped her communicate the complexities of her work more effectively, extending its reach and impact. I feel more equipped to explain the research and AI strategies in general to my clinical colleagues. Now, people reach out to me to ask, I want to work on this project. Can I use AI to answer this question? she said.

Looking to the AI-powered future

Whats next for Adedinsewos research? Taking AI mainstream within the field of cardiology. While AI tools are not currently widely used in evaluating Mayo Clinic patients, she believes they hold the potential to have a significant positive impact on clinical care.

These tools are still in the research phase, Adedinsewo says. But Im hoping that within the next several months or years we can start to do more implementation research to see how well they improve care and outcomes for cardiac patients over time.

Bhaskar Pant, executive director of MIT Professional Education, says We at MIT Professional Education feel particularly gratified that we are able to provide practitioner-oriented insights and tools in machine learning and AI from expert MIT faculty to frontline health researchers such as Dr. Demi Adedinsewo, who are working on ways to enhance markedly clinical care and health outcomes in cardiac and other patient populations. This is also very much in keeping with MITs mission of 'working with others for the betterment of humankind!'

Read more from the original source:

Putting artificial intelligence at the heart of health care with help from MIT - MIT News

Beethoven’s Unfinished 10th Symphony Brought to Life by Artificial Intelligence – Scientific American

Teresa Carey: This is Scientific Americans 60-Second Science. I'm Teresa Carey.

Every morning at five oclock, composer Walter Werzowa would sit down at his computer to anticipate a particular daily e-mail. It came from six time zones away, where a team had been working all night (or day, rather) to draft Beethovens unfinished 10th Symphonyalmost two centuries after his death.

The e-mail contained hundreds of variations, and Werzowa listened to them all.

Werzowa: So by nine, 10 oclock in the morning, its likeIm already in heaven.

Carey: Werzowa was listening for the perfect tunea sound that was unmistakably Beethoven.

But the phrases he was listening to werent composed by Beethoven. They were created by artificial intelligencea computer simulation of Beethovens creative process.

Werzowa: There werehundreds of options, and some are better than others. But then there is that one which grabs you, and that was just a beautiful process.

Carey: Ludwig van Beethoven was one of the most renowned composers in Western music history. When he died in 1827, he left behind musical sketches and notes that hinted at a masterpiece. There was barely enough to make out a phrase, let alone a whole symphony. But that didnt stop people from trying.

In 1988 musicologist Barry Cooper attempted. But he didnt get beyond the first movement. Beethovens handwritten notes on the second and third movements are meagernot enough to compose a symphony.

Werzowa: A movement of a symphony can have up to 40,000 notes. And some of his themes were three bars, like 20 notes. Its very little information.

Carey: Werzowa and a group of music experts and computer scientists teamed up to use machine learning to create the symphony. AhmedElgammal, the director of the Art and Artificial Intelligence Laboratory at Rutgers University, led the AI side of the team.

Elgammal: When you listen to music read by AIto continue a theme of music, usually its a very short few seconds, and then they start diverging and becoming boring and not interesting. They cannot really take that and compose a full movement of a symphony.

Carey: The teams first task was to teach the AI to think like Beethoven. To do that, they gave it Beethovens complete works, his sketchesand notes. They taught it Beethoven's processlike how he went from those iconic four notes to his entire Fifth Symphony.

[CLIP: Notes from Symphony no. 5]

Carey: Then they taught it to harmonize with a melody, compose a bridge between two sectionsand assign instrumentation. With all that knowledge, the AI came as close to thinking like Beethoven as possible. But it still wasnt enough.

Elgammal: The way music generation using AI works is very similar to the way, when you write an e-mail, you find that the e-mail thread predicts whats the next word for you or what the rest of the sentence is for you.

Carey: Butlet the computer predict your words long enough, and eventually, the text will sound like gibberish.

Elgammal: It doesnt really generate something that can continue for a long time and be consistent. So that was the main challenge in dealing with this project: How can you take a motif or a short phrase of music that Beethoven wrote in his sketchand continue it into a segment of music?

Carey: Thats where Werzowas daily e-mails came in. On those early mornings, he was selecting what he thought was Beethovens best. And, piece by piece, the team built a symphony.

Matthew Guzdial researches creativity and machine learning at the University of Alberta. He didnt work on the Beethoven project, but he says that AI is overhyped.

Guzdial: Modern AI, modern machine learning, is all about just taking small local patterns and replicating them. And its up to a human to then take what the AI outputs and find the genius. The genius wasnt there. The genius wasnt in the AI. The genius was in the human who was doing the selection.

Carey: Elgammal wants to make the AI tool available to help other artists overcome writers block or boost their performance. But both Elgammal and Werzowa say that the AI shouldnt replace the role of an artist. Insteadit should enhance their work and process.

Werzowa: Like every tool, you can use a knife to kill somebody or to save somebodys life, like with a scalpel in a surgery. So it can go any way. If you look at the kids, like kids are born creative.Its like everything is about being creative, creative and having fun. And somehow were losing this. I think if we could sit back on a Saturday afternoon in our kitchen, and because maybe were a little bit scared to make mistakes, ask the AI to help us to write us a sonata, song or whateverin teamwork, life will be so much more beautiful.

Carey: The team released the 10th Symphony over the weekend. When asked who gets credit for writing it Beethoven, the AIor the team behind itWerzowa insists it is a collaborative effort. But, suspending disbelief for a moment, it isnt hard to imagine that were listening to Beethoven once again.

Werzowa: I dare to say that nobody knows Beethovenas well as the AI, didas well as the algorithm. I think music, when you hear it, when you feel it, when you close your eyes, it does something to your body. Close your eyes, sit back and be open for it, and I would love to hear what you felt after.

Carey: Thanks for listening. For Scientific Americans60-Second Science, Im Teresa Carey.

[The above text is a transcript of this podcast.]

See the rest here:

Beethoven's Unfinished 10th Symphony Brought to Life by Artificial Intelligence - Scientific American

Understanding the UK Artificial Intelligence commercialisation – GOV.UK

The government is undertaking research to explore how AI R&D is successfully commercialised and brought to market.

The Department for Digital, Culture, Media and Sport (DCMS), along with the Office for Artificial Intelligence and Digital Standards and Internet Governance (DSIG), are leading the research project.

Research consultants Oxford Insights and Cambridge Econometrics have been commissioned with exploring the ways technology transfer happens for AI, and are seeking to conduct interviews with those with knowledge of the industry.

The research aims to increase understanding of the following topics:

Oxford Insights and Cambridge Econometrics would like to speak individuals with experience and knowledge of the AI development ecosystem, Innovate UK and other funding programmes, Standards Developing Organisations (SDOs), AI patents, AI R&D in the public and private sectors, AI funding and Venture Capital, and AI policy.

Our interviews will take approximately 45 mins -1 hour; however, we are happy to accommodate if time doesnt permit this length of interview. We may request your approval to follow up on specific points and themes identified across all our interactions.

Please get in touch with either aisha.naz@dcms.gov.uk or sam.hainsworth@dcms.gov.uk if you have any clarifications or questions. We look forward to working with you.

Read more here:

Understanding the UK Artificial Intelligence commercialisation - GOV.UK

What is Artificial Intelligence as a Service (AIaaS)? | ITBE – IT Business Edge

Software as a Service, or SaaS, is a concept that is familiar to many. Long-time Photoshop users will recall when Adobe stopped selling its product and instead shifted to a subscriber model. Netflix and Disney+ are essentially Movies as a Service, particularly at a time when ownership of physical media is losing ground to media streaming. Artificial Intelligence as a Service (AIaaS) has been growing in market adoption in recent years, but the uninitiated might be asking: what exactly is it?

In a nutshell, AIaaS is what happens when a company develops and licenses use of an AI to another company, most often to solve a very specific problem. For example, Bill owns a company that sells hotdogs through his e-commerce site. While Bill offers a free returns policy for dissatisfied customers, he lacks the time to provide decent customer support, and rarely replies to emails. Separately, a software developer has created a chatbot that can handle most customer inquiries using natural language processing, and often solve the issue or answer a question before human intervention is even required. For a monthly fee, the chatbot is licensed to the hotdog vendor, and implemented on his website. Now, the bot is solving 80% of customer issues, leaving Bill with the time to respond to the remaining 20%. But Bill is still too preoccupied making hotdogs, so he subscribes to a service like Flowrite, that uses AI to intelligently write his emails on the fly.

AI is also being put in service to analyze large sets of data and make predictions, streamline information storage, or even detect fraudulent activity. Amazons personal recommendation engine, an AI powered by machine learning, is now available as a licensed service to other retailers, video stream platforms, and even the finance industry. Googles suite of AI services range from natural language processing, handwriting recognition, to real-time captioning and translation. IBMs groundbreaking AI, Watson, is now being deployed to fight financial crimes, target advertisements based on real-time weather analysis, and analyze data to help hospitals make treatment judgements.

Also read: AI-Enabled Payments: A Q&A with Tradeshift

Also read: How Quantum Computing Will Transform AI

Machine learning AIs improve with time, usage, and development. Some, like YouTubes recommendation engine, have become so sophisticated that it sometimes feels like we have entire television stations tailored perfectly to our interests. Others, like language model AI GPT-3, produce entire volumes of text that are nearly indistinguishable from an authentic human source.

Microsoft has even put GPT-3 to use to translate conversational language into a working computer code, potentially opening up a new frontier in how software can be written in the future, and giving coding novices a fighting chance. Microsoft has also partnered with NVIDIA to create a new natural language generation model, three times as powerful as GPT-3. Improvements in language recognition and generation have obvious carryover benefits for the future development of chatbots, home assistants, and document generation as well.

Industrial giant Siemens has announced they are integrating Googles AIaaS solutions to streamline and analyze data, and predict, for instance, the rate of wear-and-tear of machinery on their factory floor. This could reduce maintenance costs, improve the scheduling of routine inspections, and prevent unexpected equipment failures.

AIaaS is a rapidly growing field, and there will be many more niches discovered that it can fill for years to come.

Read next: Top 5 Benefits of AI in Banking and Finance

Visit link:

What is Artificial Intelligence as a Service (AIaaS)? | ITBE - IT Business Edge

Transactions in the Age of Artificial Intelligence: Risks and Considerations – JD Supra

Artificial Intelligence (AI) has become a major focus of, and the most valuable asset in, many technology transactions and the competition for top AI companies has never been hotter. According to CB Insights, there have been over 1,000 AI acquisitions since 2010. The COVID pandemic interrupted this trajectory, causing acquisitions to fall from 242 in 2019 to 159 in 2020. However, there are signs of a return, with over 90 acquisitions in the AI space as of June 2021 according to the latest CB Insights data. With tech giants helping drive the demand for AI, smaller AI startups are becoming increasingly attractive targets for acquisition.

AI companies have their own set of specialized risks that may not be addressed if buyers approach the transaction with their standard process. AIs reliance on data and the dynamic nature of its insights highlight the shortcomings of standard agreement language and the risks in not tailoring agreements to address AI specific issues. Sophisticated parties should consider crafting agreements specifically tailored to AI and its unique attributes and risks, which lend the parties a more accurate picture of an AI systems output and predictive capabilities, and can assist the parties in assessing and addressing the risks associated with the transaction. These risks include:

Freedom to use training data may be curtailed by contracts with third parties or other limitations regarding open source or scraped data.

Clarity around training data ownership can be complex and uncertain. Training data may be subject to ownership claims by third parties, be subject to third-party infringement claims, have been improperly obtained, or be subject to privacy issues.

To the extent that training data is subject to use limitations, a company may be restricted in a variety of ways including (i) how it commercializes and licenses the training data, (ii) the types of technology and algorithms it is permitted to develop with the training data and (iii) the purposes to which its technology and algorithms may be applied.

Standard representations on ownership of IP and IP improvements may be insufficient when applied to AI transactions. Output data generated by algorithms and the algorithms themselves trained from supplied training data may be vulnerable to ownership claims by data providers and vendors. Further, a third-party data provider may contract that, as between the parties, it owns IP improvements, resulting in companies struggling to distinguish ownership of their algorithms prior to using such third-party data from their improved algorithms after such use, as well as their ownership and ability to use model generated output data to continue to train and improve their algorithms.

Inadequate confidentiality or exclusivity provisions may leave an AI systems training data inputs and material technologies exposed to third parties, enabling competitors to use the same data and technologies to build similar or identical models. This is particularly the case when algorithms are developed using open sourced or publicly available machine learning processes.

Additional maintenance covenants may be warranted because an algorithms competitive value may atrophy if the algorithm is not designed to permit dynamic retraining, or the user of the algorithm fails to maintain and retrain the algorithm with updated data feeds.

In addition to the above, legislative protection in the AI space has yet to fully mature, and until such time, companies should protect their IP, data, algorithms, and models, by ensuring that their transactions and agreements are specifically designed to address the unique risks presented by the use and ownership of training data, AI-based technology and any output data generated by such technology.

Link:

Transactions in the Age of Artificial Intelligence: Risks and Considerations - JD Supra

The 5 articles you read in AI hell – The Next Web

The devil went down to Silicon Valley; he was looking for a soul to steal. But he ended up taking a consulting gig with Palantir instead.

In the meantime, the algorithms in charge of punishing the wicked now. And these days the sign above hells gates reads Abandon Open Source, with an Amazon smile beneath the print.

Those condemned to an eternity of pain and suffering in the modern era are now forced to read the same five AI articles over and over.

Which kind of sounds like what its like to read tech news back here on Earth anyway. Dont believe me? Lets dive in.

No it wasnt. These articles usually involve a text generator such as OpenAIs GPT-3. The big idea is that the journalist will either pay for access or collaborate with OpenAI to get GPT-3 to generate text from various prompts.

The journalist will ask something silly like can AI ever truly think like a human? and then GPT-3 will use that prompt to generate a specific number of outputs.

Then, the journalists and editors go to work. Theyll pick the best responses, mix and match sentences that make the most sense, and then discard the rest.

This is the editorial equivalent of taking the collected works of Stephen King, copy/pasting a single sentence from each book into a word doc, and then claiming youve published an entirely new book from the master of horror.

In hell, you stand in a long line to read hyperbolic, made-up stories about AIs capabilities. And, as your ultimate punishment, you have to rewrite them for the next person in line.

I remember reading about an early funding round for an AI company called PredPol. It had raised several million dollars to develop an AI system capable of predicting crime before it happens.

Im sorry. Perhaps you didnt read that right. It says: predicting crime before it happens.

This is something thats impossible. And I dont mean technologically impossible, I mean not possible within the realms of classical or quantum physics.

You see crime isnt generated from hotspots like mobs spawning in an MMO every 5 minutes. A first year statistics or physics student understands that no amount of historical data can predict where new crimes will occur. Mostly because the past isnt literally prescient. But, also, its impossible to know how many crimes have actually been committed.Most crimes go unreported.

PredPol cant predict crime. It predicts arrests based on historical data. In other words: PredPol tells you where youve already arrested people and then says try there again. Simply put: it doesnt work because it cant work.

But it raised money and raised money until one day it grew into a full-grown company worth billions all for doing nothing.

In hell, you have to read funding stories about billion-dollar AI startups that dont actually do anything or solve any problems. And youre not allowed to skim.

Theres variations on this one Googles AI demonstrates a 72% reduction in racial bias, Amazons new algorithm is 87% better at spotting and removing Naziproducts from its store front and theyre all bunk.

Big techs favorite PR company is the mainstream media.

Facebook will, as a hypothetical example, say something like our new algorithms are 80% more efficient at finding and removing toxic content in real time, and thats when the telephone game starts.

Youll see half a dozen reputable news outlets printing headlines that basically say Facebooks new algorithms make it 80% less toxic. And thats simply not true.

If a chef were to tell you theyve adopted a new cooking technique that results in 80% less fecal matter being detected in the soup theyre about to serve, you probably wouldnt think that was a good thing.

Increasing the efficiency of an algorithm doesnt result in a unilateral increase in overall system efficiency. And, because statistical correlations are incredibly difficult to make when you dont have access to the actual data being discussed, the people writing up these stories are simply taking the big tech marketing teams word for it.

In hell, you have to read articles about big tech companies that only have quotes from people who work at those companies and statistics that cant possibly be verified.

Weve all read these stories. They cover the biggest issues in the world of AI as if theyre writing about the weather.

The story will be something like Clearview AI gets new government contracts, and the coverage will quote a politician, the CEO of Clearview, and someone representing law enforcement.

The gist of the piece will be Ethics aside, law enforcement agencies say these products are invaluable.

And then, way down towards the end of the article, youll see the obligatory studies have shown that facial recognition struggles to identify some faces. Experts warn against the use of such technologies until this bias can be solved.

In hell, every AI article you read starts with the sentence this doesnt work as well for Black people or women, but were just going to move past that like it isnt important.

My least favorite AI article is the ones that profess to tell me what non-experts think.

These are the articles with headlines like Study: 80% of people believe AI will be sentient within a decade and 75% of moms think Alexa is a danger to children.

These studies are typically conducted by consultancy companies that specialize in this sort of thing. And usually theyre not out conducting studies on the speculation that some journalist will find their workappealing. They get paid to do their research.

And by research, I mean: sourcing answers on Amazons Mechanical Turk or giving campus students a gift card to fill out a survey.

These studies are often bought and paid for ahead of time by an AI company as a marketing tool.

These pitches, in my inbox, usually look something like Hey Tristan, did you hear that 92% of CEOs dont know what Kubernetes is? Are you interested in this exclusive study and a conversation with Dr Knows Itall, founder of the Online School For Learning AI Good? They can speak to the challenges of hiring quality IT talent.

Can you spot the rubbish?

In hell, the algorithm tells you that you can read articles covering actual computer science research as soon as you finish reading all the vapid survey pieces on AI published in mainstream outlets.

But youre never done are you? Theres always another. What do soccer dads think about gendered voice assistants? What percentage of people think data is a character on Star Trek? Will driverless cars be a reality in 2022? Heres what Tesla owners think.

Yes, AI hell is a place filled with horrors beyond comprehension. And, just in case you havent figured it out yet, were already here. This article has been your orientation.

Now if youll just sign in to Google News, well get started (Apple News is currently not available in hell due to legal issues concerning the App Store).

See the original post here:

The 5 articles you read in AI hell - The Next Web

SenseTime Co-hosts the 3rd International Artificial Intelligence Fair to Nurture AI Talent and Promote a Collaborative Education Ecosystem -…

Since launching in July this year, the highly anticipated IAIF has attracted 665 project submissions from over 300 schools in 8 countries and regions, with 121 projects from 98 schools selected for the final online presentation and verbal Q&A.During the final competition presentations, the project submissions were reviewed meticulously by 45 professional judges from top-tier universities, enterprises and research institutions, including University of Science and Technology of China, Tsinghua University, Fudan University, Shanghai Jiao Tong University, Nanyang Technological University, Peking University, Chinese University of Hong Kong and Shanghai Technology Art Center. The teaching and evaluation system of martial arts based on body posture recognition and machine learning by Li Lufei from Shanghai Nanyang Model High School and Wu Keyu from the High School Affiliated to Fudan University as well as the drone powered by OpenCV for flood fight and rescue by Huang Pucheng, Wang Bingyang and Lin Yinhang from Zhejiang Wenling High School became the winners of the grand prize.

Besides, the research of rehabilitation assessment and training system powered by 3D hand posture verification by Zhang Yihong from Shanghai World Foreign Language Academy stood out from many excellent projects and won the first prize. Leveraging the 3D hand posture verification, this project aims to design a low-cost and easy-to-operate product for the patient with hand movement disorders, realizing 89.9% accurate in assessment of hand rehabilitation and training.

Lin Junqiu, Deputy Director of Science and Education Department from Shanghai Science, Art and Education Center, said, "Artificial intelligence is critical to our future. As we continue to advance technology development, we must cultivate a larger pool of AI talent with even higher levels of expertise and innovation capability. The huge opportunities brought by the AI era will facilitate transformative applications across industry verticals and scenarios but also formulate optimal collaboration between human being and artificial intelligence."

Lynn Dai, General Manager of SenseTime's Education Product, said at the final competition, "AI has become an important driving force for technological innovation, we believe the IAIF can provide an innovative platform for young people to develop their interest in AI. Meanwhile, SenseTime Education is dedicated to nurturing young talent and broadening their horizons with advanced insights from an industry perspective, as well as preparing them for the AI-empowered future."

IAIF is also providing comprehensive services for participants, from scientific innovation training to project incubation, helping them solve practical industrial problems. The IAIF organizing committee hosted a four-week AI training course for students before the final competition. The students from the most outstanding project teams will have the chance to participate in other national or international competitions. In addition, the students from the most outstanding IAIF projects will participate in a roadshow training workshop for startups as part of incubator programmes organized by SenseTime; the company will provide technology for high-potential projects.

"IAIF provided me with a unique opportunity to exchange ideas on this exciting AI topic with participants from different schools around the world," said Wu Keyu, the winner of the grand prize. "Through this competition, I have gained a better understanding of the powerful impact from AI and humans working together to build novel solutions that will create a better tomorrow for human society."

The success of the 3rd International Artificial Intelligence Fair not only marks the formation of the foundations for the AI education ecosystem developed by the Shanghai Xuhui Education Bureau and SenseTime, but also boosts the collaboration among governments, academia, enterprises and industries in AI technology innovation. In the future, SenseTime Education will continue to act as a focal point and a platform for cultivating future AI talents.

About SenseTime

SenseTime is a leading AI software company focused on creating a better AI-empowered future through innovation. Upholding a vision of advancing the interconnection of the physical and digital worlds with AI, driving sustainable productivity growth and seamless interactive experiences, SenseTime is committed to advancing the state of the art in AI research, developing scalable and affordable AI software platforms that benefit businesses, people and society, and attracting and nurturing top talents, shaping the future together.

With our roots in the academic world, we invest in our original and cutting-edge research that allows us to offer and continuously improve industry-leading, full-stack AI capabilities, covering key fields across perception intelligence, decision intelligence, AI-enabled content generation and AI-enabled content enhancement, as well as key capabilities in AI chips, sensors and computing infrastructure. Our proprietary AI infrastructure, SenseCore, allows us to develop powerful and efficient AI software platforms that are scalable and adaptable for a wide range of applications.

Today, our technologies are trusted by customers and partners in many industry verticals including Smart Business, Smart City, Smart Life and Smart Auto.

We have offices in markets including Hong Kong, Mainland China, Taiwan, Macau, Japan, Singapore, Saudi Arabia, the United Arab Emirates, Malaysia, and South Korea, etc., as well as presences in Thailand, Indonesia and the Philippines. For more information, please visit SenseTime's website as well as its LinkedIn, Twitter and Facebook pages.

SOURCE SenseTime

See original here:

SenseTime Co-hosts the 3rd International Artificial Intelligence Fair to Nurture AI Talent and Promote a Collaborative Education Ecosystem -...

Alation Acquires Artificial Intelligence Vendor Lyngo Analytics – Business Wire

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Alation Inc., the leader in enterprise data intelligence solutions, today announced the acquisition of Lyngo Analytics, a Los Altos, Calif.-based data insights company. The acquisition will elevate the business user experience within the data catalog, scale data intelligence, and help organizations drive data culture. Lyngo Analytics CEO and co-founder Jennifer Wu and CTO and co-founder Joachim Rahmfeld will join the company.

Lyngo Analytics uses a natural language interface to empower users to discover data and insights by asking questions using simple, familiar business terms. Alation offers the most intelligent and user-friendly machine-learning data catalog on the market. And by integrating Lyngo Analytics artificial intelligence (AI) and machine-learning (ML) technology into its platform, Alation deepens its support for the non-technical user, converting natural language questions into SQL.

The integration lowers the barrier to entry for business users. Now, they can acquire and develop data-driven insights from across an enterprise's broad range of data sources. This means even data consumers without SQL expertise can ask questions in natural language and find data and insights without the support of data analysts. The acquisition will help organizations drive data culture by putting data and analytics into the hands of the masses.

Wu will join Alation as Senior Director of Product Management, where she will be responsible for product strategy and delivery for natural language data search, discovery, and exploration experiences. Rahmfeld, who is also a part-time, graduate-level deep learning and natural language processing lecturer at UC Berkeleys Master of Information and Data Science Program, will be Senior Director of AI/ML Research. He will be responsible for Alations AI and machine learning center of excellence, building both platform and application experiences that leverage AI and ML to enhance Alations value for business and technical users.

Alation created the first machine learning data catalog and were known for providing the most user-friendly interface on the market, said Raj Gossain, Chief Product Officer, Alation. With this acquisition, were building on the best. Were doubling down on key aspects of the platform that will help drive data culture and spur innovation and growth. Jennifer and Joachim developed a unique solution for a complex data and analytics issue, and Im excited to welcome them to the Alation team.

The acquisition is the latest milestone for Alation, which announced a $110 million Series D funding round and a $1.2 billion market valuation in June 2021. Alation is growing quickly, earning the trust of nearly 300 customers, including leading global brands such as Cisco, Exelon, GE Aviation, Munich Re, NASDAQ, and Pfizer. The company has more than 450 employees globally and is hiring. Recently, Alation was named a leader in The Forrester Wave: Data Governance Solutions, Q3 2021 report and Snowflakes Data Governance Partner of the Year.

Learn More:

About Alation

Alation is the leader in enterprise data intelligence solutions including data search & discovery, data governance, data stewardship, analytics, and digital transformation. Alations initial offering dominates the data catalog market. Thanks to its powerful Behavioral Analysis Engine, inbuilt collaboration capabilities, and open interfaces, Alation combines machine learning with human insight to successfully tackle even the most demanding challenges in data and metadata management. Nearly 300 enterprises drive data culture, improve decision making, and realize business outcomes with Alation including AbbVie, American Family Insurance, Cisco, Exelon, Fifth Third Bank, Finnair, Munich Re, NASDAQ, New Balance, Parexel, Pfizer, US Foods and Vistaprint. Headquartered in Silicon Valley, Alation was named to Inc. Magazines Best Workplaces list and is backed by leading venture capitalists including Blackstone, Costanoa, Data Collective, Dell Technologies, Icon, ISAI Cap, Riverwood, Salesforce, Sanabil, Sapphire, and Snowflake Ventures. For more information, visit alation.com.

The rest is here:

Alation Acquires Artificial Intelligence Vendor Lyngo Analytics - Business Wire

Vilsack working with FDA on animal biotechnology – National Hog Farmer

Despite the signing of a Memorandum of Understanding on animal biotechnology at the end of the Trump administration between the USDA and the Department of Health and Human Services, animal biotechnology approvals remain stalled. Secretary of Agriculture Tom Vilsack says hes committed to working with the Food and Drug Administration on creating proper jurisdiction of animal biotech oversight, but concerns exist on the originally signed MOU.

Animal biotechnology refers to genetic altering of animals through a range of potential processes, including recombinant DNA techniquesand genome editing, to improve certain traits or characteristics of these animals. These practices have the potential to develop resistance and mitigate diseases including zoonotic infections like SARS-CoV-2 and avian influenza, to reduce methane emissions, improve heat tolerance, and much more.

Currently, these technologies are regulated by FDA under its animal drug authority, through a process that has proven prohibitively onerous. To date, only two animals intended for agricultural purposes have ever been approved by the FDA for domestic use, both taking decades for full approval.

The National Pork Producers Council says it supports giving USDA regulatory authority over gene editing in food animals, pointing out that the agencys Animal and Plant Health Inspection Service already has a review process in place for gene editing in plants, which can serve as a model for livestock. Under a USDA-proposed rule, the agency would have primary regulatory jurisdiction of gene-edited animals.

Ahead of a hearing in the House Agriculture Committee on livestock issues, nearly two-thirds of the committee (37 members) signed and sent a letter to Vilsack and FDA Acting Commissioner Janet Woodcock urging timely progress in the reform of regulatory frameworks and animal biotechnology products. Lawmakers cited genetic improvements as a hallmark of agriculture and called on USDA Vilsack and Woodcock to make improvements that would modernize the regulatory system for animal genetics and assure timely adoption of biotechnology innovations.

Related:HHS, USDA sign MOU on animal biotechnology

Rep. Vicki Hartzler, R-Mo., asked Vilsack during the hearing when a pig that has been found to be resistant to PRRScould be used by producers. Vilsack responded that he shares her goal of instituting an appropriate regulatory structure to use the tools and innovations available. There are ways in which we have to work collaboratively with our friends at FDA to make sure our regulatory system is able to respond quickly enough and be able to keep pace with the pace of change, the secretary told House Ag members.

In questioning from Rep. Jim Baird, R-Ind., who serves as the ranking member of the House Agriculture Committees subcommittee on biotechnology, Baird notes that concerns on the cumbersome regulatory process sends the wrong message and tends to stifle innovation.

Innovation has been the very backbone of agriculture throughout time. In the last several decades, that innovation has begun to look different as the technology has changed, but the goal remains the same to create the safestand most sustainable, abundant, and stable food supply in the world, says Baird.

The unfortunate reality though, is that our regulatory system has not kept up with this technology and has created a near-impossible challenge to get these products to market, Baird says. USDA needs to take the lead in developing new, risk and science-basedregulatory pathways that encourage agricultural innovation, provide access to valuable new technologies to American livestock producers, and ensurefood safety and security for consumers.

During the hearing, Vilsack said as a department, USDA attempted to reach an agreement with HHS and FDA during the Trump administration with an original MOU signed, however, the then FDA administrator was not supportive of transferring oversight of animal products to USDA.

Related: Animal gene editing turf war battle continues

Vilsack says hes not sure HHS published the memorandum as there were some concerns on whether HHS had adequate authority to sign the memorandum. Vilsack says theyre now in the process to take a look at the MOU and determining whether or not there are steps that need to be taken to make sure we have bright lines between what we do and what FDA does.

Kevin Scott, a soy grower from Valley Springs, South Dakotaand American Soybean Association president, welcomed the bipartisan letter.

With devastating animal diseases at our nations doorstep, the need for genetic innovations to protect our flocks and herds has never been greater. Representatives Plaskett and Baird should be commended for leading the House Agriculture Committee in this impressive bipartisan appeal for much-needed biotechnology regulatory modernization to protect our nations livestock. We urge our countrys regulators to heed their call, says Scott.

ASA agrees that the existing regulatory process for review of animals using biotechnology innovations needs to be streamlined for more timely adoption and applauds the legislators letter.

Originally posted here:
Vilsack working with FDA on animal biotechnology - National Hog Farmer

PDS Biotechnology Announces Conference Call and Webcast to – GlobeNewswire

FLORHAM PARK, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Companys proprietary Versamune T-cell activating technology, will release financial results for the third quarter of 2021 on Wednesday, November 10, 2021, before the market opens. Following the release, management will host a conference call to review the companys financial results and provide a business update.

The conference call is scheduled to begin at 8:00 am ET on Wednesday, November 10, 2021. Participants should dial 877-407-3088 (United States) or 201-389-0927 (International) and mention PDS Biotechnology. A live webcast of the conference call will also be available on the investor relations page of the Company's website at http://www.pdsbiotech.com.

After the live webcast, the event will be archived on PDS Biotechs website for 6 months.

About PDS BiotechnologyPDS Biotech is a clinical-stage immunotherapy company developing a growing pipeline of cancer immunotherapies based on the Companys proprietary Versamune T-cell activating technology platform. Our Versamune-based products have demonstrated the potential to overcome the limitations of current immunotherapy by inducing in vivo, large quantities of high-quality, highly potent polyfunctional tumor specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has developed multiple therapies, based on combinations of Versamune and disease-specific antigens, designed to train the immune system to better recognize diseased cells and effectively attack and destroy them. The companys pipeline products address various cancers including breast, colon, lung, prostate and ovarian cancers. To learn more, please visit http://www.pdsbiotech.com or follow us on Twitter at @PDSBiotech.

About PDS0101PDS Biotechs lead candidate, PDS0101, combines the utility of the Versamune platform with targeted antigens in HPV-expressing cancers. In partnership with Merck & Co., PDS Biotech is evaluating a combination of PDS0101 and KEYTRUDA in a Phase 2 study in first-line treatment of recurrent or metastatic head and neck cancer. PDS Biotech is also conducting two additional Phase 2 studies in advanced HPV-associated cancers and advanced localized cervical cancer with the National Cancer Institute (NCI) and The University of Texas MD Anderson Cancer Center, respectively.

Forward Looking StatementsThis communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the Company) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Companys management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as may, will, should, would, expect, anticipate, plan, likely, believe, estimate, project, intend, forecast, guidance, outlook and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Companys ability to protect its intellectual property rights; the Companys anticipated capital requirements, including the Companys anticipated cash runway and the Companys current expectations regarding its plans for future equity financings; the Companys dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Companys operations or require the Company to relinquish rights to the Companys technologies or product candidates; the Companys limited operating history in the Companys current line of business, which makes it difficult to evaluate the Companys prospects, the Companys business plan or the likelihood of the Companys successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS0101, PDS0203 and other Versamune based products; the future success of such trials; the successful implementation of the Companys research and development programs and collaborations, including any collaboration studies concerning PDS0101, PDS0203 and other Versamune based products and the Companys or monitoring committees or other third parties interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Companys product candidates; the success, timing and cost of the Companys ongoing clinical trials and anticipated clinical trials for the Companys current product candidates, including statements regarding the timing of initiation, pace of enrollment, significance of milestones, and completion of the trials (including our ability to fully fund our disclosed clinical trials, which assumes no material changes to our currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim results, which are not necessarily indicative of the final results of the Companys ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the acceptance by the market of the Companys product candidates, if approved; the timing of and the Companys ability to obtain and maintain U.S. Food and Drug Administration or other regulatory authority approval of, or other action with respect to, the Companys product candidates; and other factors, including legislative, regulatory, political and economic developments not within the Companys control, including unforeseen circumstances or other disruptions to normal business operations arising from or related to COVID-19. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the risk factors included in the Companys annual and periodic reports filed with the SEC. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.

Media & Investor Relations Contact:Deanne RandolphPDS BiotechPhone: +1 (908) 517-3613Email: drandolph@pdsbiotech.com

Rich CockrellCG CapitalPhone: +1 (404) 736-3838Email: rich@cg.capital

Read the original post:
PDS Biotechnology Announces Conference Call and Webcast to - GlobeNewswire

AcureX Therapeutics to Present at Oppenheimer Biotechnology Emerging Science Summit – Yahoo Finance

SAN CARLOS, Calif., October 11, 2021--(BUSINESS WIRE)--AcureX Therapeutics Corporation, a privately-held preclinical-stage biotechnology company focused on developing disease altering therapeutics for neurodegenerative diseases, today announced that it was selected to present at the Oppenheimer Biotechnology Emerging Science Summit on October 15th, 2021.

Presentation details:

Halting Neurodegeneration with Miro1 Directed TherapiesPresented by: William Shrader, Ph.D., Co-founder and CEO AcureX TherapeuticsDate and time: October 15th, 2021 at 1:30p.m. ET / 10:30a.m. PT

The Oppenheimer Biotechnology Emerging Science Summit will be held virtually and will feature Stanford Universitys SPARK program. Presentations will be given by experts in the fields of oncology, immunology, neurology, and gene therapy, as well as management from several publicly traded companies.

William Shrader, Ph.D. said, "We at AcureX are pleased to be recognized as a leader in an emerging field and we are delighted to share our novel drug discovery approach at this prestigious forum."

About AcureX Therapeutics

The mission of AcureX Therapeutics is to halt neurodegenerative diseases driven by impaired mitophagy, starting with Parkinsons Disease. AcureX expects to have one or more late-preclinical therapeutic candidates for Parkinsons in human trials within two years, followed by candidates for other neurodegenerative diseases. AcureXs novel approach and founding intellectual property are based on recent discoveries made by the companys inventor and co-founder, Xinnan Wang MD, Ph.D. AcureX has built a unique target and drug discovery platform to accelerate drug development and de-risk clinical trials with an exclusive license to the founding intellectual property. The AcureX team is led by veteran scientists with a proven track record in CNS drug development and serial life sciences entrepreneurs. For more information, please visit https://www.acurex.com.

Story continues

Oppenheimer Biotechnology Emerging Science Summit Registration

To express interest, please contact your Oppenheimer Institutional Salesperson or email Deena Sullivan at Deena.Sullivan@opco.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20211011005102/en/

Contacts

Ashley Gonzalez, Ph.D.Info@acurex.com

Read the original post:
AcureX Therapeutics to Present at Oppenheimer Biotechnology Emerging Science Summit - Yahoo Finance

US Analytical instrument Market Report 2021-2025: Focus on Pharmaceutical and Biotechnology, Food and Beverage, & Environmental Testing -…

DUBLIN--(BUSINESS WIRE)--The "Analytical instrument Market in US 2021-2025" report has been added to ResearchAndMarkets.com's offering.

The analytical instrument market in the US is poised to grow by $ 5.57 bn during 2021-2025, progressing at a CAGR of almost 3%.

The market is driven by the rise in demand for generic drugs and stringent government regulations. This study also identifies the decline in the price of PV systems as one of the prime reasons driving the analytical instrument market in the US growth during the next few years.

The report on analytical instrument market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors. The report offers an up-to-date analysis regarding the current us market scenario, latest trends and drivers, and the overall market environment.

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading analytical instrument market in US vendors that include ABB Ltd., Agilent Technologies Inc., AMETEK Inc., Bio-Rad Laboratories, Inc, Bruker Corp., Danaher Corp., General Electric Co., Honeywell International Inc., Mitsubishi Electric Corp., and Siemens AG.

Also, the analytical instrument market in US analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Key Topics Covered:

Executive Summary

Market Landscape

Market Sizing

Five Forces Analysis

Market Segmentation by Product

Market Segmentation by End-user

Customer landscape

Vendor Landscape

Vendor Analysis

Appendix

For more information about this report visit https://www.researchandmarkets.com/r/ue0qgq

Read more:
US Analytical instrument Market Report 2021-2025: Focus on Pharmaceutical and Biotechnology, Food and Beverage, & Environmental Testing -...

Biotechnology can be used to improve condition of farmers, says Ethanol man – The Indian Express

Renowned industrialist and founder chairman of Praj Industries, Dr Pramod Chaudhari, who is popularly known as the Ethanol man, recently said that agricultural inputs form the base of biotechnology and these can be used to uplift the socio-economic status of farmers. Dr Chaudhari was speaking at an event held in his honour and hosted by United Western Business Forum at Hotel Sayaji in Wakad.

Dr Chaudhari was felicitated by Dr Anand Deshpande, the CMD of Persistent Systems, for being the first Indian recipient of the prestigious George Washington Carver Award, 2020.

Pune Mayor Murlidhar Mohol and PMRDA (Pune Metropolitan Region Development Authority) Commissioner Dr Suhas Diwase also attended the programme.

Dr Chaudhari said that biofuels are redefining transportation fuel mix and they also help combat climate change as they have low carbon content. The use of agricultural feedstock for production of biofuels provided an additional source of income to farmers, he added. Dr Chaudhari said that bio-based renewable chemicals and materials are the new frontier of bioeconomy.

Mohol said Dr Chaudharis achievement is a matter of pride for Puneites and added that People like Dr Chaudhari will inspire the youth of the city.

Dr Deshpande said an entrepreneur should always think about achieving the next level for his business, because any business can stagnate after reaching a certain level of success. He also suggested that a wide base of mentors was required to guide the entrepreneurs through difficult times.

The dean of alumni and corporate relations at IIT Bombay, Dr Suhas Joshi, said that the institute was in advanced stages of discussions with Dr Chaudhari for setting up a lifelong learning centre for IIT-B alumni. The institute has a strong base of over 65,000 alumni working across various segments and they have an urge to learn new skills from their alma mater, Joshi added.

Dr Diwase pointed out that biotechnology had the potential to make agriculture sustainable and economically viable. This will also help reduce urban influx and ease pressure on cities, he said. The current Covid-19 pandemic has shown the youth the importance of moving back to the fields rather than seeking opportunities in big cities, he said.

Go here to read the rest:
Biotechnology can be used to improve condition of farmers, says Ethanol man - The Indian Express

Investors in Clal Biotechnology Industries (TLV:CBI) from three years ago are still down 50%, even after 16% gain this past week – Simply Wall St

It's nice to see the Clal Biotechnology Industries Ltd. (TLV:CBI) share price up 16% in a week. Meanwhile over the last three years the stock has dropped hard. Tragically, the share price declined 56% in that time. So the improvement may be a real relief to some. After all, could be that the fall was overdone.

While the stock has risen 16% in the past week but long term shareholders are still in the red, let's see what the fundamentals can tell us.

See our latest analysis for Clal Biotechnology Industries

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

Clal Biotechnology Industries became profitable within the last five years. That would generally be considered a positive, so we are surprised to see the share price is down. So given the share price is down it's worth checking some other metrics too.

We note that the dividend seems healthy enough, so that probably doesn't explain the share price drop. We like that Clal Biotechnology Industries has actually grown its revenue over the last three years. But it's not clear to us why the share price is down. It might be worth diving deeper into the fundamentals, lest an opportunity goes begging.

You can see below how earnings and revenue have changed over time (discover the exact values by clicking on the image).

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for Clal Biotechnology Industries the TSR over the last 3 years was -50%, which is better than the share price return mentioned above. This is largely a result of its dividend payments!

Clal Biotechnology Industries shareholders are down 5.6% for the year (even including dividends), but the market itself is up 48%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. However, the loss over the last year isn't as bad as the 7% per annum loss investors have suffered over the last half decade. We would want clear information suggesting the company will grow, before taking the view that the share price will stabilize. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Clal Biotechnology Industries has 4 warning signs (and 1 which is significant) we think you should know about.

For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on IL exchanges.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

See the article here:
Investors in Clal Biotechnology Industries (TLV:CBI) from three years ago are still down 50%, even after 16% gain this past week - Simply Wall St

Cellumed and ARTES Sign Development and License Agreement – b3c newswire

Accelerate development of GMP-grade production enzymes essential for manufacturing mRNA-based biopharmaceuticals

SEOUL, Korea and LANGENFELD, Germany, October 13, 2021 / B3C newswire / -- Today, Cellumed Co. Ltd., listed stock market company and Germany based ARTES Biotechnology GmbH announce the execution of a Development and License Agreement aiming at the generation of microbial production cell lines, processes and documentation for the cGMP manufacturing of two enzymes required in the manufacturing process of mRNA vaccines.

Under this agreement, ARTES shall be responsible for the development of high yield microbial cell lines expressing two recombinant enzymes. Further steps at ARTES will include the development of up- and downstream processes as well as of the analytical assays to characterize the two products. Results will be transferred by ARTES to its German CMO partner Richter-Helm BioLogics GmbH & Co. KG for subsequent cGMP production. The project management will be supported by ARTES Korean representative Quality by Design, Inc.

Cellumed predicts that the mRNA platform will gradually expand product development in the future as a base technology with high potential for developing other vaccines and therapeutics even after COVID-19 subsides. Therefore, Cellumed will realize technological independence of materials through the localization of production enzymes, which are key raw materials for mRNA vaccines. In addition, it is planning to supply production enzymes in Korea first, and is also planning to gradually advance into the global market.

Statement of Dr. Michael Piontek, Managing Director of ARTES Biotechnology: We are very proud being chosen by Cellumed for this important task of supporting the establishment of most up-to-date mRNA technology in South-Korea. We will contribute our long term experience in recombinant biotechnology and will give all our outstanding expertise and know-how in this collaboration. We are looking forward to building a strong and long lasting relation with Cellumed.

About CellumedCellumed is leading the field of tissue graft materials based on human-derived biomaterials, leading the localization of artificial joints and succeeding in establishing a recombinant protein production system that cultivates a large amount of growth factors for treatment. In addition, it is the best musculoskeletal medical device specialist in Korea, developing various products by combining excellent biotechnology and biomaterials and leading to high value-added of existing products.Cellumed was established in 1997 under the corporate philosophy of respect for human beings and received approval for establishment of a human tissue bank from the Ministry of Food and Drug Safety (MFDS) in 2005. Cellumed's human tissue bank is processed and distributed into safe and excellent tissue graft materials by specialized researchers. Products are continuously researched and developed.Cellumed succeeded in developing and mass-producing rhBMP2, a recombinant protein derived from animal cells (CHO Cell), for the first time in Asia and for the second time in the world. In addition to rhBMP2, we have also succeeded in developing various recombinant protein growth factors such as BMP4, BMP7, GDF5, TGF-1, and FGF7 so that more people can lead a healthy life. We will become the most competitive global bio company in the world through innovative bio product portfolios.

About ARTESARTES Biotechnology GmbH is a Germany-based company specialized in recombinant protein production, process and vaccine (VLP-based) development from microbial expression systems. ARTES offers generation of optimized production cell lines in proprietary yeast expression systems based on Hansenula polymorpha and in bacteria. In addition to genetic engineering, the company provides fermentation and downstream process development, analytical assay development and production cell line characterization. ARTES operates worldwide from its 850 sqm S1 facilities in Langenfeld.

Contact

ARTES Biotechnology GmbHDr. Melanie Piontek+49 2173 27587 12This email address is being protected from spambots. You need JavaScript enabled to view it.

Keywords: Cell Line; Technology; Cell Culture Techniques; Culture Media; Cell Proliferation; Cell Line Development; Cells, Cultured; Recombinant Proteins; Productivity; Biological Products; RNA, Messenger; Commerce; Republic of Korea; Germany

Published by B3C newswire

Read more from the original source:
Cellumed and ARTES Sign Development and License Agreement - b3c newswire

Insider insights on getting into, and thriving, during medical school | University of Michigan – Michigan Medicine

Its no secret that getting accepted into medical school is highly competitive, and for those who are admitted, making the choice of which school to attend can feel overwhelming.

Hearing insights and advice directly from those who have successfully navigated the process and are currently thriving in medical school ahead of you, though, can be invaluable.

Here, five University of Michigan medical students share their experiences for current and future applicants, breaking down some of the most asked about elements of the process (you can also watch their livestream Q&A video above.).

Kelsey, fourth-year medical student: I think it's important to think about your most important experiences to you. I would pick three or four things that feel really meaningful. I was an EMT prior to coming to medical school. I made sure I really had crafted my story around that and what was important for me to share. I also was a middle school teacher. I thought through those experiences and what valuable lessons I learned from those and what I want to convey to an interviewer. It's important to practice with friends and family.

In general, there's kind of standard interview questions that get asked at a lot of different interviews: what are your strengths, what are your weaknesses, what's a challenge you have overcome. Having a couple of prepared answers will help alleviate a lot of stress when youre interviewing.

Chelsie, second-year medical student: I had never in my life been interested in cardiology. Now I'm interested in doing a cardiology fellowship. It was due to me being able to reach out to faculty and talk to them about their experiences. It's not like having to beg or pull teeth. Michigan is a great institution with brilliant faculty members. People who are leading their fields. To be able to work with these people, learn from them, hear about their backgrounds and how they got to where they are, in hopes of maybe me getting there one day, it's so inspiring. It gives you more fuel to keep going when you have faculty who validate you constantly.

Matt, first-year medical student: One thing that is unique or nearly unique about Michigan Medical School is we only do one preclinical year. It is a true pass or fail. I've been blown away the first few weeks of school. We had a quiz after the first week and folks were sending their big study guides they put together in our class group chats. The preclinical year is six blocks. Those are little terms, with midterms in there. You have a final block exam at the end of each of those blocks, which range from four weeks to ten weeks.

Kelsey: Clinical year is great. We do it the second year versus the third year. You do a bunch of rotations. You have so much responsibility if you want it. You answer pages, you go see your patients, and you really get to own them. But, at the end of the day, I have residents, an intern, a senior faculty and an attending faculty who are all looking over my shoulder and making sure I'm not making mistakes when it comes to taking care of the patient. It's incredible learning without the scary pressure that youre going to mess anything up.

I can wholeheartedly say the Michigan process works, and you learn a lot. I feel really ready and excited for residency.

SEE ALSO: What does it take to get into Michigans medical school? Just ask the new dean

Quintin, fourth-year medical student: Not only are we getting the experience of being able to perform things, write notes, come up with differential diagnoses, and fully manage our patients as best we can with a lot of the guidance that was discussed, but we are also allowed to flex our teaching minds.

You realize as a medical student that its really helpful to have a resident who is interested in teaching, and I am one of those people who is very interested in it. So it was nice to work on that now, see what works and see what I can carry forward or what would I change as I move forward into residency.

Xinghao, second-year MSTP student: Our learning community, M-Home, has a lot of spirit. It's about support and community, and that's important. My house counselor, Christine, Ive cried to her on multiple occasions. I will admit that. If you end up in Fitzbutler House, you probably will cry to her too. Medical school is hard. Life is hard. Definitely having a support system that cares about your emotions and how happy you feel in school makes it all worth it.

Continue reading here:
Insider insights on getting into, and thriving, during medical school | University of Michigan - Michigan Medicine

Unraveling the Mystery of Touch | Harvard Medical School – Harvard Medical School

Some parts of the bodyour hands and lips, for exampleare more sensitive than others, making them essential tools in our ability to discern the most intricate details of the world around us.

This ability is key to our survival, enabling us to safely navigate our surroundings and quickly understand and respond to new situations.

Get more HMS news here

It is perhaps unsurprising that the brain devotes considerable space to these sensitive skin surfaces that are specialized for fine, discriminative touch and which are continually gathering detailed information via the sensory neurons that innervate them.

But how does the connection between sensory neurons and the brain result in such exquisitely sensitive skin?

A new study led by researchers at Harvard Medical School has unveiled a mechanism that may underlie the greater sensitivity of certain skin regions. The research, conducted in mice and published Oct. 11 in Cell, shows that the overrepresentation of sensitive skin surfaces in the brain develops in early adolescence and can be pinpointed to the brain stem.

Moreover, the sensory neurons that populate the more sensitive parts of the skin and relay information to the brain stem form more connections and stronger ones than neurons in less sensitive parts of the body.

This study provides a mechanistic understanding of why more brain real estate is devoted to surfaces of the skin with high touch acuity, said senior author David Ginty, the Edward R. and Anne G. Lefler Professor of Neurobiology at Harvard Medical School. Basically, it's a mechanism that helps explain why one has greater sensory acuity in the parts of the body that require it.

While the study was done in mice, the overrepresentation of sensitive skin regions in the brain is seen across mammalssuggesting that the mechanism may be generalizable to other species.

From an evolutionary perspective, mammals have dramatically varied body forms, which translates into sensitivity in different skin surfaces. For example, humans have highly sensitive hands and lips, while pigs explore the world using highly sensitive snouts. Thus, Ginty said this mechanism could provide the developmental flexibility for different species to develop sensitivity in different areas.

Moreover, the findings, while fundamental, could someday help illuminate the touch abnormalities seen in certain neurodevelopmental disorders in humans.

Scientists have long known that certain body parts are overrepresented in the brainas depicted by the brains sensory map, called the somatosensory homunculus, a schematic of human body parts and the corresponding areas in the brain where signals from these body parts are processed. The striking illustration includes cartoonishly oversized hands and lips.

Previously, it was thought that the overrepresentation of sensitive skin regions in the brain could be attributed to a higher density of neurons innervating those skin areas. However, earlier work by the Ginty lab revealed that while sensitive skin does contain more neurons, these extra neurons are not sufficient to account for the additional brain space.

We noticed that there was a rather meager number of neurons that were innervating the sensitive skin compared to what wed expect, said co-first author Brendan Lehnert, a research fellow in neurobiology, who led the study with Celine Santiago, also a research fellow in the Ginty lab.

It just wasnt adding up, Ginty added.

To investigate this contradiction, the researchers conducted a series of experiments in mice that involved imaging the brain and neurons as neurons were stimulated in different ways.

First, they examined how different skin regions were represented in the brain throughout development. Early in development, the sensitive, hairless skin on a mouses paw was represented in proportion to the density of sensory neurons.

However, between adolescence and adulthood, this sensitive skin became increasingly overrepresented in the brain, even though the density of neurons remained stablea shift that was not seen in less sensitive, hairy paw skin.

This immediately told us that theres something more going on than just the density of innervation of nerve cells in the skin to account for this overrepresentation in the brain, Ginty said.

It was really unexpected to see changes over these postnatal developmental timepoints, Lehnert added. This might be just one of many changes over postnatal development that are important for allowing us to represent the tactile world around us, and helping us gain the ability to manipulate objects in the world through the sensory motor loop that touch is such a special part of.

Next, the team determined that the brain stemthe region at the base of the brain that relays information from sensory neurons to more sophisticated, higher-order brain regionsis the location where the enlarged representation of sensitive skin surfaces occurs.

This finding led the researchers to a realization: The overrepresentation of sensitive skin must emerge from the connections between sensory neurons and brain stem neurons.

To probe even further, the scientists compared the connections between sensory neurons and brain stem neurons for different types of paw skin. They found that these connections between neurons were stronger and more numerous for sensitive, hairless skin than for less sensitive, hairy skin. Thus, the team concluded, the strength and number of connections between neurons play a key role in driving overrepresentation of sensitive skin in the brain.

Finally, even when sensory neurons in sensitive skin werent stimulated, mice still developed expanded representation in the brainsuggesting that skin type, rather than stimulation by touch over time, causes these brain changes.

We think we've uncovered a component of this magnification that accounts for the disproportionate central representation of sensory space. Ginty said. This is a new way of thinking about how this magnification comes about.

Next, the researchers want to investigate how different skin regions tell the neurons that innervate them to take on different properties, such as forming more and stronger connections when they innervate sensitive skin.

What are the signals? Ginty asked. Thats a big, big mechanistic question.

And while Lehnert described the study as purely curiosity-driven, he noted that there is a prevalent class of neurodevelopmental disorders in humans called developmental coordination disorders that affect the connection between touch receptors and the brainand thus might benefit from elucidating further the interplay between the two.

This is one of what I hope will be many studies that explore on a mechanistic level changes in how the body is represented over development, Lehnert said. Celine and I both think this might lead, at some point in the future, to a better understanding of certain neurodevelopmental disorders.

Co-investigators included Erica Huey, Alan Emanuel, Sophia Renauld, Nusrat Africawala, Ilayda Alkislar, Yang Zheng, Ling Bai, Charalampia Koutsioumpa, Jennifer Hong, Alexandra Magee, and Christopher Harvey of Harvard Medical School.

The research was supported by the National Institutes of Health (F32 NS095631-01, F32-NS106807, K99 NS119739, DP1 MH125776, R01 NS089521, and R01 NS97344), a William Randolph Hearst Fellowship, a Goldenson Fellowship, a Harvard Medical School Deans Innovation Grant in the Basic and Social Sciences, and the Edward R. and Anne G. Lefler Center for the Study of Neurodegenerative Disorders.

Read more from the original source:
Unraveling the Mystery of Touch | Harvard Medical School - Harvard Medical School

Dallas ISD and UT Southwestern partner to open a new kind of school – Dallas ISD

Science starts here for the next generation of students entering a PK-8 biomedical school in the heart of Dallas medical district. Dallas ISD and the UT Southwestern Medical Center (UTSW) together will launch a new transformation school slated to open its doors next fall.

The Medical District PK-8 Biomedical School will start by serving scholars in prekindergarten through first grade, expanding one grade level each year up to eighth grade.

The curriculum will immerse students in science, technology, engineering, and mathematics (STEM) by introducing real-world experiences in biomedical science. These daily explorations, centered on a STEM-based curriculum, will also provide firsthand exposure and direct access to innovative field trip opportunities.

The unique partnership is one of the first in the nation to focus on biomedical science for elementary students at a medical institution.

This school model is another game-changer for students as the district joins hands with an incredible partner to reimagine learning, said Michael Hinojosa, superintendent of Dallas ISD. It also highlights how science continues to evolve in a unique, relatable, and innovative way with students as young as three years old. This partnership will help connect students with cutting-edge resources that develop them into the next generation of scientists and medical professionals.

The Medical District PK-8 Biomedical School will have no academic requirements or attendance boundaries. Enrollment offers are generated at random, through a lottery system, based on the number of seats available in each grade coupled with the students priority group.

This exciting endeavor underscores what it takes to build and inspire the next generation of physicians and scientists instilling a love for science in children at an early age, said W. P. Andrew Lee, M.D., Executive Vice President for Academic Affairs, Provost, and Dean, UT Southwestern Medical School. Our hope is that the added hands-on experiences and education they will gain during their years at the Medical District PK-8 Biomedical School will be the beginning of a lifelong connection to math, science, and discovery.

Fifty percent of the seats are reserved for economically disadvantaged students and 50 percent are offered to non-economically disadvantaged students.

The school will be located on the UTSW campus at 6516 Forest Park Road. Families may apply during the application period from Nov. 1 to Jan. 31, 2022.

For more information, visit http://www.dallasisd.org/medicaldistrictschool.

See the article here:
Dallas ISD and UT Southwestern partner to open a new kind of school - Dallas ISD

UB featured in PBS Newshour story – UB Now: News and views for UB faculty and staff – University at Buffalo Reporter

The Jacobs School of Medicine and Biomedical Sciences was featured prominently in a story that aired on PBS Newshour on Oct. 13.

Part of an ongoing series called Rethinking College, the story described how, since the start of the pandemic, theres been a surge of interest in health sciences programs from nursing to medicine to public health. The segment noted that many medical schools are seeing double-digit increases in applicants since the pandemic began and that the Jacobs School saw a 40% jump in the number of applications for the class that started at UB in August.

The story also mentioned that this phenomenon is often dubbed the Fauci effect, after Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, who has guided much of the nations pandemic response.

But in an on-camera interview, Dori Marshall, director of admissions in the Jacobs School, noted that such an effect was unlikely to be the cause behind the spike in applications, since applying to medical school is not something people can do on the spur of the moment. Its really a process that takes years to get themselves ready to apply to medical school, she said.

The piece included an interview with Ming Lian, a first-year student at the Jacobs School, who worked on her medical school applications for two years.

Marshall noted that the increase in applications was more likely due to the fact that the pandemic caused medical schools to move the entire process, including interviews, online. The expense of flying here was gone, she said.

Lian agreed. Being able to do it virtually and at home saved me quite a bit of money, she said, adding that allowed her to apply to more medical schools.

That virtual aspect had a major effect, in particular, on increasing the numbers of applications from first-generation college students like Lian, who moved to the U.S. from a village in China when she was 13 years old.

The story reported that last year, UB saw a 59% jump in the number of applications from first-generation college students, a demographic that has long been underrepresented in medical schools.

Lians reaction when she found out she had been accepted? That was incredible, she said. That was an incredible feeling.

The story already has received significant viewership. According to Nielsen ratings at the program's website, 2.7 million people watch the program each night. The website has nearly 2 million unique visitors; its Youtube channel has 2.77 million subscribers, and this story has received more than 5,700 views so far. And the story was tweeted from a Twitter account that has 1.1 million followers.

Read this article:
UB featured in PBS Newshour story - UB Now: News and views for UB faculty and staff - University at Buffalo Reporter

Hispanic Heritage Month a time to celebrate and take inclusive steps – UMass Medical School

The UMass Chan Medical School will gather virtually on Thursday, Oct. 14, for its annual celebration of Hispanic Heritage Month.

Hispanic Heritage Month began as a weeklong celebration in 1968 to highlight the achievements and contributions of Latinx people in the United States. It became a monthlong celebration in 1988 through the passing of a bill put forth by the Hispanic Congressional Caucus, led by U.S. Rep. Esteban Torres. Celebrated Sept. 15 to Oct. 15, it centers on the independence of several Latin American countries, including Guatemala, Honduras, El Salvador, Nicaragua and Costa Rica, with Mexico, Chile and Belizes independence celebrations falling a few days later.

Activists and academics alike are advocating to rename the celebration to include the term Latinx, to further gender inclusivity and to encompass the multiple ethnicities from which Latinx people come.

The monthlong heritage celebration is a time to pause and take note of the work that is yet to be done around the inclusion and representation of Latinx peoples. The Association of American Medical Colleges Diversity in Medicine report, which is generated every three years, noted in 2019 that only 5.4 percent of active physicians identified as Latinx. Socioeconomic factors such as lack of access to financial assistance for medical school and psychosocial factors such as lack of mentorship and representation impact these numbers.

Given that patients are more likely to see a doctor and schedule follow up appointments when they feel heard and seen, especially by medical practitioners who look like them, this figure is especially alarming during the COVID-19 global pandemic. The risk of infection, hospitalization and death caused by the virus is 2.3 times higher in Latinx communities, the highest of all communities of color, according to the Centers for Disease Control.

As Latinx people are projected to comprise the majority of the U.S. population by 2045, the celebration of Hispanic Heritage Month and the concerns Latinx communities face are national concerns.

The historic gift that UMass Chan Medical School received from The Morningside Foundation, initiatives such as the Worcester Pipeline Collaborative and groups like SACNAS (Society for the Advancement of Chicanos and Native Americans in Science) are intentional means to address such disparities.

On Thursday, Oct. 14, at noon, the UMass Chan Medical School community will join the nation in celebration of Esperanza: A Celebration of Hispanic Heritage and Hope. Participants will reflect on all the contributions Hispanics have made in the past and will continue to make in the future. Quinsigamond Community College President Luis Pedraja, PhD, will deliver the keynote. RSVP to celebrate the strides the community has made in the past and the hope they have for the future.

Read the original:
Hispanic Heritage Month a time to celebrate and take inclusive steps - UMass Medical School